PT-141 (Bremelanotide)
FDA-approved melanocortin receptor agonist (Vyleesi) for hypoactive sexual desire disorder. Acts centrally on MC3R/MC4R to restore sexual motivation without
Buy more, save more
Total Price
$75
For research & laboratory use only. Not for human consumption.
Half-Life
~2.7 hours
Administration Route
Subcutaneous injection
Central Arousal Pathway
MC4R agonist acts in hypothalamus, not genitals — true CNS arousal
Rapid Onset
Effects within 45-60 minutes; 12-hour activity window
Both Sexes
Effective in male and female arousal disorder research
Effect Profile
Libido
Arousal
Hormonal Balance
Confidence
Effect Timeline
Arousal onset; hypothalamic MC4R activation within 1 hour
Peak effect window; maximum arousal and sensitivity
Effect duration; gradual return to baseline
No dependence; can repeat 2–3x weekly in research
Start — 45–90 min
Arousal onset; hypothalamic MC4R activation within 1 hour
4–6 hours
Peak effect window; maximum arousal and sensitivity
12 hours
Effect duration; gradual return to baseline
After protocol
No dependence; can repeat 2–3x weekly in research
Mechanism of Action
Scientific Research
Obstet Gynecol (2019)
Ann N Y Acad Sci (2003)
J Sex Med (2006)
Product FAQs
Stacks Well With
Kisspeptin-10
C-terminal decapeptide of kisspeptin that activates GPR54 to trigger GnRH pulse release, driving LH, FSH, and testosterone surges. Central regulator of the
Oxytocin
Hypothalamic neuropeptide that modulates social behaviour, trust, bonding, and stress responses. Widely studied for autism spectrum conditions, PTSD, and
Related Products
Kisspeptin-10
C-terminal decapeptide of kisspeptin that activates GPR54 to trigger GnRH pulse release, driving LH, FSH, and testosterone surges. Central regulator of the
Oxytocin
Hypothalamic neuropeptide that modulates social behaviour, trust, bonding, and stress responses. Widely studied for autism spectrum conditions, PTSD, and